Clinical Trial of a Rapidly Cycling, Non-Cross Reactive Regimen of Approved Therapeutic Agents to Treat Prostate Cancer

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 09 Feb 2024

Price :

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

Drugs Abiraterone acetate (Primary) ; Cabazitaxel (Primary) ; Carboplatin (Primary) ; Enzalutamide (Primary) ; Prednisone (Primary) ; Radium 223 chloride (Primary)
Indications Adenocarcinoma; Bone metastases; Prostate cancer
Focus Therapeutic Use
Acronyms PRINT

27 Jan 2024 Results assessing the efficacy of treating mCRPC with a rapidly cycling, noncross-reactive regimen as a way to more effectively treat an intrinsic heterogeneous disease, delay or prevent drug resistance, and minimize treatment toxicity presented at the 2024 Genitourinary Cancers Symposium
10 Dec 2021 Status changed from recruiting to completed.
08 Jun 2021 Results (cut-off : 1/03/2021, n=31) presented at the 57th Annual Meeting of the American Society of Clinical Oncology.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com